Real-world observations on neuroinflammation-related drug responses in Alzheimer's disease.
Alzheimer's risk varies with neuroinflammation-linked conditions. Certain drugs like levothyroxine and mirabegron may lower AD risk, while levetiracetam and quetiapine may increase it - a crucial finding for personalized treatment.
This study analyzed real-world data to investigate the associations between drug exposure and Alzheimer's disease (AD) incidence in patients with neuroinflammation-related conditions like alcohol use disorder, epilepsy, hemorrhagic stroke, and traumatic brain injury. The researchers used covariate-adjusted Cox models to estimate hazard ratios (HRs) of drug exposure on AD, identifying neuroinflammation-specific drug responses. They found three drugs (levothyroxine, mirabegron, and ropinirole) had lower HRs, while two drugs (levetiracetam and quetiapine) had higher HRs in individuals with neuroinflammation-related conditions compared to those without. These findings suggest the importance of considering neuroinflammation status when selecting medications to manage cognitive health in Alzheimer's disease.